Is Titan Biotech overvalued or undervalued?

As of 4 July 2025, Titan Biotech's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, with a PE ratio of 17.57, an EV to EBITDA ratio of 14.77, and a Price to Book Value of 2.47. These metrics suggest that Titan Biotech's stock price does not align well with its earnings and asset values compared to its peers.
In comparison to its industry peers, Titan Biotech's PE ratio is notably lower than that of Solar Industries, which stands at 125.92, but still higher than Godrej Industries, which is valued attractively at 40.05. The EV to EBITDA ratio of Titan is also less favorable when compared to peers like Gujarat Fluoroch at 34.70 and Deepak Nitrite at 24.84. While Titan Biotech has shown strong historical returns, including a remarkable 490.52% over the past five years, its recent performance has lagged behind the Sensex, with a year-to-date decline of 37.50%.